Eduard J van Beers
Universiteit Utrecht
H-index: 29
Europe-Netherlands
Top articles of Eduard J van Beers
Use of the oxygen gradient ektacytometry in the dose titration of hydroxyurea therapy in children with sickle cell disease
International journal of laboratory hematology
2024/4
Eduard J Van Beers
H-Index: 17
The RoxyScan is a novel measurement of red blood cell deformability under oxidative and shear stress
Scientific Reports
2024/3/15
Eduard J Van Beers
H-Index: 17
Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment
Haematologica
2024/3/3
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency
Blood advances
2024/2/8
Eduard J Van Beers
H-Index: 17
Hanny Al-Samkari
H-Index: 17
Vanessa Beynon
H-Index: 10
Kevin Hm Kuo
H-Index: 12
Diagnosis and management of pyruvate kinase deficiency: international expert guidelines
2024/2/5
Hanny Al-Samkari
H-Index: 17
David C Rees
H-Index: 35
Satheesh Chonat
H-Index: 11
Kevin Hm Kuo
H-Index: 12
Eduard J Van Beers
H-Index: 17
A novel composition of endogenous metabolic modulators improves red blood cell properties in sickle cell disease
Ejhaem
2024/2/2
Eduard J Van Beers
H-Index: 17
Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
Blood advances
2024/1/23
Safety and Efficacy of Mitapivat in Adult Patients with Erythrocyte Membranopathies (SATISFY)
Blood
2023/11/28
Eduard J Van Beers
H-Index: 17
Kevin Hm Kuo
H-Index: 12
P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
HemaSphere
2023/8/1
P1427: RARE ANAEMIA DISORDERS EUROPEAN EPIDEMIOLOGICAL PLATFORM (RADEEP): DISTRIBUTION OF PATIENTS AFFECTED BY RADS IN EUROPE
HemaSphere
2023/8/1
PB2518: OPTIMIZING THE DETECTION OF 2, 3-DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT
HemaSphere
2023/8/1
P1477: MITAPIVAT EFFICACY IN ADULTS WITH PYRUVATE KINASE DEFICIENCY AND BASELINE HEMOGLOBIN LEVELS> 10 G/DL
HemaSphere
2023/8/1
P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT–A SUB-ANALYSIS OF THE ACTIVATE TRIAL
HemaSphere
2023/8/1
P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA–A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY
HemaSphere
2023/8/1
P1481: SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA
HemaSphere
2023/8/1
P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED
HemaSphere
2023/8/1
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective
2023/8/1
Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme
2023/6/12
Kevin Hm Kuo
H-Index: 12
Eduard J Van Beers
H-Index: 17
5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH …
HemaSphere
2023/4/1
The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design
BMJ open
2023/3/1
